High systemic CD4 memory T cell counts assessed by peripheral blood samples prior to initiation of PD-L1/PD-1 blockade therapy can serve as a reliable predictive biomarker for NSCLC patients, in addition, dynamic changes in CD4 T cell memory populations can be successfully used. This evidence concerns the gene CD274 and non-small cell lung carcinoma.